Global Chronic Obstructive Pulmonary Disease Industry

Global Chronic Obstructive Pulmonary Disease Industry

This report analyzes the worldwide markets for Chronic Obstructive Pulmonary Disease in US$ Million. The report provides separate comprehensive analytics for US and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 53 companies including many key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A. SICAR, Schering-Plough Corporation, Sepracor, Inc., and Vectura Group plc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE MCP-6220
A GLOBAL MARKET REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Respiratory Diseases - Common and Serious II-1
COPD - A Debilitating Disease II-1
COPD Fact File: Prevalence II-2
COPD Fact File: Mortality II-2
COPD Fact File: Smoking as the Leading Cause II-2
COPD - Economic Burden II-2
Table 1: COPD Related Costs (Including Direct and Indirect
Costs) Per Patient Aged Over 40 Years (includes corresponding
Graph/Chart) II-3

2. MARKET DYNAMICS II-4
Current & Future Analysis II-4
Market Overview II-4
Market Outlook II-4
Maintenance Therapies to Continue Lead II-5
Treatment of Inflammation - An Unmet Need II-5
Competitive Landscape II-6
Table 2: World COPD Market by Major Drugs (2006): Value Sales
for Advair, Spiriva, Combivent, Symbicort, and Atrovent
(includes corresponding Graph/Chart) II-6

Table 3: World Leading Inhaled COPD/Asthma Drugs (2007):
Value Sales for Advair, Symbicort, Pulmicort, Flovent,
Asmanex, Serevent, Foradil, Spiriva, Atrovent, Combivent
(includes corresponding Graph/Chart) II-7

3. COPD PIPELINE II-8
The COPD Drug Discovery II-8
Bronchodilators Pipeline II-8
List of Potential Bronchodilator (LABA Inhaled) Candidates
in Drug Development Pipeline II-8
List of Potential Bronchodilator (LAMA Inhaled) Candidates
in Drug Development Pipeline II-8
Anti-inflammatories Pipeline II-9
List of Potential Anti-inflammatory (Inhaled
Corticosteroid) Candidates in Drug Development Pipeline II-9
List of Potential Anti-inflammation Agents (Anti-
Leukotriene-oral) Candidates in Drug Development Pipeline II-9
List of Potential Anti-inflammation Agents (
Phophodiesterase-4 Inhibitors-oral) Candidates in Drug
Development Pipeline II-9
Combination Products Pipeline II-9
List of Potential Combination Products (LABA/ICS
Combination-inhaled) in Drug Development Pipeline II-9
List of Potential Combination Products (LABA/LAMA) in Drug
Development Pipeline II-10
Pipeline Drugs with Novel Mode of Action II-10
List of Novel Approaches to COPD Treatment in Drug
Development Pipeline II-10

4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE - THE CONDITION AND
TREATMENT II-11
Chronic Obstructive Pulmonary Disease - Synopsis II-11
The Normal Lung Functioning II-11
The Lung Functioning in COPD II-11
Risk Factors II-11
Signs and Symptoms II-12
Diagnosis II-12
The Misconception II-12
Management Guidelines II-13
GOLD Recommended Management of COPD: Stage 0 II-13
GOLD Recommended Management of COPD: Stage II II-13
GOLD Recommended Management of COPD: Stage III II-14
GOLD Recommended Management of COPD: Stage IV II-14
Treatment Options II-14
Therapeutic Options II-15
Bronchodilators II-15
Beta2-agonists II-15
Short-acting Beta2-agonists II-16
List of Prescription Short-acting Beta2-agonists II-16
Long-acting Beta2-agonists II-16
A Comparison of Leading Two LABAs : Salmeterol and
Formoterol II-17
List of Prescription Long-acting Beta2-agonists II-17
Anticholinergics II-17
Short-acting Anticholinergics II-18
List of Short-acting Prescription Anticholinergics II-18
Long-acting Anticholinergics II-18
Methylxanthines II-18
List of Methylxanthines and Their Route of Administration II-19
Anti-inflammatories II-19
Inhaled Steroids II-19
List of Inhaled Steroids and their Route of Administration II-19
Oral Steroids II-20
List of Tablet Steroids and their Route of Administration II-20
Combination Therapies II-20
List of Prescription Combination Products II-20

5. RECENT INDUSTRY ACTIVITY II-21
AEterna Zentaris Signs Agreement to Acquire All AEZS-130
Assets from Ardana II-21
Nycomed and Forest Sign Exclusive US Accord for Daxas II-21
Schering-Plough Revises Collaboration with Novartis II-21
AstraZeneca Extends Research Collaboration with Dynavax II-22
GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal
for Adoair II-23
SeQual Technologies and AOTI Form Partnership II-23
Revotar Biopharma Secures Research Grant II-23
Argenta Discovery Announces Milestone Achievement II-23
Vectura Receives Milestone Payment II-24
Vectura Inaugurates New Laboratory Facility II-24
MicroDose Technologies Announces Name Change to MicroDose
Therapeutx II-24
Boehringer Ingelheim to Take Over Actimis Pharmaceuticals II-24
Novartis to Acquire Pulmonary Unit of Nektar II-25
Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition II-25
Sepracor, Arrow Announce Global Agreement for Combination
Inhalation Solution II-25
Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement II-26
Sepracor, Arrow Sign Technology License and Development
Agreement II-26
Teva Specialty Pharmaceuticals Announces Respiratory Deal
with UCB II-27
3M Drug Delivery and Cambridge Consultants Sign Exclusive
Agreement II-27
Sanofi-aventis Announces Collaboration with Johns Hopkins
University II-27
Lupin Enters Long-Term Accord with Forest Laboratories II-27
Ingen Signs Agreements with Batterjee Medical and Progressive
International II-28
AstraZeneca, Silence Therapeutics Enter into Collaboration II-28
Vectura Announces Sandoz as Partner for VR315 and VR632 II-28
Air Products Divests A&J Care and COPD Services II-28
Parion Sciences Receives Milestone Payment for Pulmonary
Disease Drug II-29
Almirall Receives Payment from Forest Laboratories for
Aclidinium Bromide II-29
AstraZeneca Announces EPO Ruling for Symbicort Patent II-29
Inverness Medical Announces Alere Medical Acquisition II-29
Respironics Takes Over J.H. Emerson II-29
Alkermes Enters into Joint Collaboration with Indevus
Pharmaceuticals II-30
Aradigm Enters into Collaboration Agreement with CyDex II-30
Critical Therapeutics and Dey Sign Co-Promotion Agreement II-30

6. PRODUCT APPROVALS / INTRODUCTIONS II-31
AstraZeneca Wins US Approval for Symbicort II-31
Novartis Secures EC Approval for New Oral COPD Drug, Onbrez
Breezhaler II-31
Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA II-31
Nycomed Files for Daxas® Approval with the FDA II-32
Novartis Receives FDA’s CRL for Investigational COPD
Bronchodilator, QAB149 II-32
3M Drug Delivery Launches Two New Dry Powder Inhalers II-32
GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50 II-32
Dey’s Perforomist Inhalation Solution Wins FDA Approval for COPD II-33
Boehringer, Pfizer Win EU Approval for Spiriva Respimat II-33

7. FOCUS ON SELECT PLAYERS II-34
AstraZeneca Plc (UK) II-34
Boehringer Ingelheim GmbH (Germany) II-34
GlaxoSmithKline PLC (UK) II-34
Novartis AG (Switzerland) II-35
Nycomed S.C.A. SICAR (Switzerland) II-36
Schering-Plough Corporation (US) II-36
Sepracor, Inc. (US) II-37
Vectura Group plc (UK) II-37

8. GLOBAL MARKET PERSPECTIVE II-39
Table 4: World Recent Past, Current & Future Analysis for
Chronic Obstructive Pulmonary Disease by Geographic Region -
US and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2006 through
2015 (includes corresponding Graph/Chart) II-39

Table 5: World 10-Year Perspective for Chronic Obstructive
Pulmonary Disease by Geographic Region - Percentage Breakdown
of Dollar Revenues for the US and Rest of World Markets for
2006, 2009 & 2015 II-39


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current & Future Analysis III-1
COPD - Prevalence III-1
Table 6: COPD Prevalence Data in American Adults Aged 18
Years and Over in the US (includes corresponding
Graph/Chart) III-1
Chronic Bronchitis Data III-2
Table 7: Chronic Bronchitis - Breakdown of Chronic
Bronchitis Patients by Gender: 2007 III-2

Table 8: Chronic Bronchitis - Breakdown of Chronic
Bronchitis Patients by Age Group: 2007 (includes
corresponding Graph/Chart) III-2

Table 9: Chronic Bronchitis - Breakdown of Chronic
Bronchitis Patients by Ethnicity: 2007 (includes
corresponding Graph/Chart) III-3
Emphysema Data III-3
Table 10: Emphysema - Breakdown of Chronic Bronchitis
Patients by Gender: 2007 III-3
Table 11: Emphysema - Breakdown of Chronic Bronchitis
Patients by Age Group: 2007 (includes corresponding
Graph/Chart) III-3

Table 12: Emphysema - Breakdown of Chronic Bronchitis
Patients by Ethnicity: 2007 (includes corresponding
Graph/Chart) III-4
Market Overview III-4
Table 13: US COPD Market by Major Drugs (2006): Value
Sales for Advair, Spiriva, Combivent, Flovent, Atrovent,
and Serevent (includes corresponding Graph/Chart) III-4

Table 14: US COPD Market by Major Drugs (2006): Total
Prescriptions for Advair, Spiriva, Combivent, Flovent,
Atrovent, and Serevent (includes corresponding Graph/Chart) III-5

Table 15: US COPD/Asthma Market by Drug Class (2007 and
2008): Value Sales for Inhaled Steroids/ Combinations,
Inhaled Beta Agonists, Leukotrines, and Inhaled
Anticholinergics/NSAIDs (includes corresponding
Graph/Chart) III-5

Table 16: US COPD/Asthma Market by Drug Class (2007 and
2008): Total Prescriptions for Inhaled Steroids/
Combinations, Inhaled Beta Agonists, Leukotrines, and
Inhaled Anticholinergics/NSAIDs (includes corresponding
Graph/Chart) III-6

Table 17: US COPD/Asthma Market by Leading Drugs (2007 and
2008): Value Sales for Advair/Diskus, Singulair, Spiriva,
Symbicort, Pulmicort, and Flovent (includes corresponding
Graph/Chart) III-6

Table 18: US COPD/Asthma Market by Leading Drugs (2007 and
2008): Total Number of Prescriptions for Advair/Diskus,
Singulair, Spiriva, Symbicort, Pulmicort, and Flovent
(includes corresponding Graph/Chart) III-7
Patient Non-compliance Hinders Market Growth III-7
Lack of Awareness - A Major Bottleneck for Market Growth III-7
HFA-propelled Inhalers End the CFC-propelled Inhalers Era III-8
Strategic Corporate Developments III-8
Product Approvals / Launches III-13
Select Players III-15
B.Market Analytics III-16
Table 19: US Recent Past, Current & Future Analysis for
Chronic Obstructive Pulmonary Disease - Annual Revenue
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-16

2. REST OF WORLD III-17
A.Market Analysis III-17
Current & Future Analysis III-17
China III-17
Market Overview III-17
Strategic Corporate Developments III-17
Product Approvals III-22
Select Players III-23
B.Market Analytics III-27
Table 20: Rest of World Recent Past, Current & Future
Analysis for Chronic Obstructive Pulmonary Disease - Annual
Revenue Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-27


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 56)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 28
Canada 1
Japan 4
Europe 18
France 3
Germany 2
The United Kingdom 6
Italy 1
Rest of Europe 6
Asia-Pacific (Excluding Japan) 5
------------------------------------------